OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Rheumatology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	1471
Research in Brief	1246
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	489
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	307
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	216
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	191
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	119
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	105
Reigniting the burnt-out health-care workforce	93
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	92
Can contextual factors improve clarity of the results from clinical trials of low back pain?	90
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	86
Patient involvement in digital rheumatology: lessons from practice	84
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	81
A disseminated gonococcal infection with spinal locations	77
Biological disease-modification in axial spondyloarthritis: insights from MRI	70
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	67
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	66
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	65
Research in Brief	65
Women in rheumatology in Africa	65
Assessing glucocorticoid toxicity: are the measures sensitive enough?	60
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	60
Early-stage Dupuytren's disease treatment; a promising next step?	58
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	55

Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	54
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	52
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	51
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	50
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	47
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	45
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	44
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	44
Correction to Lancet Rheumatol 2026; 8: e5–6	44
Biosimilars and the era of interchangeability	43
Additional SARS-CoV-2 vaccine doses: a little is better than none	43
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	43
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	43
Research in Brief	42
ANCA-associated large and small vessel vasculitis with aorto-pulmonary-renal syndrome	42
Clinical hypnosis and pain management in sharp debridement of skin ulcers in immune-mediated inflammatory diseases	42
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study	42
Optimal non-opioid analgesic combinations after total hip arthroplasty – Authors' reply	40
Constitutional symptoms of severe childhood-onset polyarteritis nodosa	39
Clinical trial design: time to accelerate the pace of change?	38
Urgent reform needed for homecare medicines services	38
Kanon Jatuworapruk: bringing out the enjoyment in life	36
Let's talk about sex in interstitial lung disease	36
Correction to Lancet Rheumatol 2025; 7: e851–63	35
Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study	35
Global access to biological disease-modifying drugs	34
Tackling heterogeneity in Sjögren's disease	33
Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study	32
Fetal and maternal outcome in the pregnancies of patients with systemic sclerosis and very early diagnosis of systemic sclerosis in France: a prospective study	32
Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial	32
Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study	32
Advancing research and equity through collaboration	31
The 2024 US election—voting for equitable health care	31
Pneumococcal vaccine in adults with immune-mediated inflammatory diseases	30
Are we ready for home spirometry for systemic sclerosis-associated ILD?	30
Sex differences of brain oscillatory activity and quantitative sensory testing in people with chronic osteoarthritis pain: a cross-sectional study	30
Explanation for substandard of care comparators in rheumatology randomised trial protocols	30
Suspending methotrexate for 2 weeks after COVID-19 vaccination	30
Digital self-management for back pain in the UK	30
Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal	30
Correction to Lancet Rheumatol 2025; published online Feb 27. https://doi.org/10.1016/S2665-9913(24)00348-5	29
Intra-articular botulinum toxin A injection for painful base-of-thumb osteoarthritis: a double-blind, randomised, controlled, phase 3 trial (RHIBOT)	29
Enabling and supporting public and patient involvement in arthritis research	29
Research in Brief	29
Challenges in the therapeutic management of psoriatic arthritis	29
Better diagnostic tools needed for biopsy-negative giant cell arteritis	28
Can we prevent the onset of rheumatoid arthritis in patients with high-risk features?	28
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national co	28
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level	28
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study	28

JIA care under the microscope	27
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort	27
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials	26
Cranial involvement in giant cell arteritis	26
For SLE activity and glucocorticoids: aim low	26
Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis – Authors' reply	25
Microscopic polyangiitis presenting with retinal frosted branch angiitis	25
Beneficial side-effects of colchicine for patients with gout	25
Reconciling immunotherapy and autoimmunity: not for the faint of heart	24
Penélope Palominos: rheumatology by sight and touch	24
Polychondritis in a child	24
Sex-related differences in health-care use in adult patients with inflammatory arthritis in Ontario, Canada: a population-based cohort study	24
Coronary polyarteritis nodosa	24
The impact of COVID-19 on care of early inflammatory arthritis in the UK	23
Sex and gender impact on achievement of remission in people with rheumatoid arthritis in Switzerland: a cohort study	23
COP27 Climate Change Conference: urgent action needed for Africa and the world	23
Pain and wellbeing in young people with arthritis	23
Jean Liew: from Bronte scholar to social media influencer	23
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study	22
How long do revised and multiply revised hip replacements last? A retrospective observational study of the National Joint Registry	22
Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study	22
Systemic sclerosis and pregnancy: advancing prospective evidence for risk stratification and postpartum care	22
Gout in central Asia: a few things make a big difference	22
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial	22
Top priorities for prehabilitation in orthopaedics	22
Advancing predictive accuracy for shoulder replacement surgery	21
Vascular Ehlers-Danlos syndrome: a heritable condition with potentially fatal consequences	21
Coronary polyarteritis nodosa in a young adult	21
Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study	21
Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case–control study	21
Role of plasma exchange in ANCA-associated vasculitis – Authors' reply	20
Prevention of psoriatic arthritis: the next frontier	20
Rheumatology congresses post COVID-19: we cannot regress	20
Ustekinumab with or without methotrexate for psoriatic arthritis?	20
DAVIX: a vascular outcome measure in systemic sclerosis	20
Effectiveness of a fourth mRNA dose among individuals with systemic autoimmune rheumatic diseases during the Omicron era	19
Vasculitis management remains a challenge during pregnancy	19
Research in Brief	19
Correction to Lancet Rheumatol 2023; 5: e461–73	18
Prize trends in rheumatology: the Gender Award Gap	18
Time to revisit the therapeutic benefits of exercise for osteoarthritis?	17
Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities	17
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study	17
The same genotype gives rise to a spectrum of disorders	17
Substantiation of trophoblast transport of maternal anti-SSA/Ro autoantibodies in fetuses with rapidly progressive cardiac injury: implications for neonatal Fc receptor blockade	17
Digital remote monitoring in rheumatology: using health economics to support wider adoption	17
Palliative care in patients with rheumatic diseases	17
Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	17
Occupational therapist-led versus rheumatologist-led care in people with hand osteoarthritis in Norway: an open-label, multicentre, randomised controlled, non-inferiority trial	17
Pregnant pause in women with rheumatoid arthritis	17
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality among patients who are immunocompromised with COVID-19 in Hong Kong: a retrospective cohort study	17
Susac syndrome: challenges of interpreting treatment data in a rare disease	17
Debate over interventional procedures for chronic spine pain	16
Research in Brief	16
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr	16
Research in Brief	16
Research in Brief	16
Vasculitis: the promising road ahead	15
Diffuse alveolar haemorrhage during pregnancy in systemic lupus erythematosus	15
Correction to Lancet Rheumatol 2022; 4: e177–87	15
Time to talk to adults with rheumatic diseases about herpes zoster vaccination	15
Interosseous tendon inflammation in the hands of patients with clinically suspect arthralgia: analysis of MRI data from a prospective cohort study	15
Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-	15
Cardiovascular risk in gout: time for action	15
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study	15
Correction to Lancet Rheumatol 2022; 4: e853–63	15
Rheumatic cognitive impairment: a new clinical entity?	14
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine	14
The influence of safety warnings on the prescribing of JAK inhibitors	14
Psoriatic arthritis: strategy shaping treatment	14
Calcium pyrophosphate deposition disease	14
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study	14
Forging ahead on fibromyalgia	14
Herpes zoster vaccination and flares in rheumatic diseases	14
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series	13
Getting better at quantifying the toxicity of glucocorticoids	13
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study	13
Predictors of pregnancy outcomes in SLE	13
Michael Barrett: navigating hostile terrain	13
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, obse	13

Progressive bone destruction of the hand in Gorham–Stout disease	13
Promise and challenges of mesenchymal stromal cell therapy in severe SLE	13
Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial	13
An imaging crisis in axial spondyloarthritis	12
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study	12
Predictors of pregnancy outcomes in SLE	12
Modelling allopurinol-induced severe adverse cutaneous reactions	12
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial	12
Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis: a systematic review and individual participant data meta-analysis	12
Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people	12
Aspirin desensitisation in pregnant individuals with autoimmune disease	12
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study	12
Preclinical or subclinical rheumatoid arthritis-associated interstitial lung disease: misleading terms with potentially deleterious consequences	12
Narendra Kumar Bagri: taking paediatric rheumatology in India to new heights	12
Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study	12
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus – Authors' reply	12
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis	12
Inclusion of pregnant populations in clinical trials in China: the ethical considerations	11
Debashish Danda	11
Research in Brief	11
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study	11
Contesting the BACPAP consortium's consensus – Authors' reply	11
Long COVID in inflammatory rheumatic diseases—what's in a name?	11
Self-management of gout using a mobile app	11
Coronary polyarteritis nodosa in a young adult – Authors' reply	11
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	11
Including refractory systemic sclerosis-associated GAVE in research agendas	11
Research in Brief	11
Kimberly Templeton: creative change maker	11
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease	11
Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study	10
The stark reality of living with arthritis in the UK	10
Dual JAK and ROCK inhibition and comorbidities in rheumatoid arthritis	10
Correction to Lancet Rheumatol 2022; 4: e262–73	10
Immunosuppression and SARS-CoV-2 breakthrough infections	10
Barriers to CAR T-cell therapy in rheumatology	10
Synovial tissue for personalised medicine in rheumatoid arthritis: hype or hope?	10
Early screening for rheumatoid arthritis-associated interstitial lung disease: statistical nuances challenge the role of disease activity – Authors' reply	10
Risk-based stratified primary care for common musculoskeletal pain presentations (STarT MSK): a cluster-randomised, controlled trial	10
Precision medicine in rheumatoid arthritis: unravelling sex-driven differences in response to treatment	9
When the game changes: efficacy of rituximab in systemic sclerosis	9
Irish experiences of parenting with early inflammatory arthritis: a qualitative study	9
Botulinum toxin A: a short-term treatment option for base-of-thumb osteoarthritis?	9
Colchicum and gout: two millennia of therapeutic continuity	9
Research in Brief	9
Improvement of a giant cell arteritis prediction model	9
The Gout by Dorian Haskard	9
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study	9
From whole-brain metrics to circuit-specific precision: advancing fMRI biomarkers for TNF inhibitor response in rheumatoid arthritis	9